Sign in
UBX Stock Price, Chart, Stats & News
Unity Biotechnology, Inc.
Save
3.44M
Market cap
–
Current P/E
–
Forward P/E
UBX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 20.33% |
Operating margin | -1569.50% |
Pretax margin | -1673.42% |
Net margin | -1673.42% |
Effective tax rate | – |
ROA | -73.23% |
ROE | -326.28% |
D/E | -110.28x |
Interest coverage ratio | – |
UBX valuation
P/E | – |
P/S | 2.59x |
P/B | -16.47x |
P/CF | -0.19x |
P/FCF | -0.20x |
P/OCF | -0.19x |
PEG | 0.03x |
EV multiple | 0.53x |
About
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases.
Similar securities
Based on sector and market capitalization
Report issue